Morgan Stanley Downgrades QLT Inc (QLTI) to Underweight
More News related to QLTI
- QLT Inc. (QLTI) Announces $50M Dutch Tender Offer
- QLT to repurchase up to US$ 50 million of common shares - Modified "Dutch Auction" tender offer to commence on or about December 4, 2008
- Beacon Equity Issues Technical Trade Alerts on Market Movers: INCY, QLTI, LINTA, PDGI, FRPT, SVNT
- QLT Inc (QLTI) CEO Buys 15K Shares
- Allergan Reports Third Quarter 2008 Operating Results
More News related to Downgrades
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Morgan Stanley downgrades QLT Inc (Nasdaq: QLTI) from Equalweight to Underweight.
QLT Inc. is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, photodynamic therapy and Atrigel.
Related Categories
DowngradesStocks Mentioned
+0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
